Welcome to our dedicated page for Fate Therapeutic SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fate Therapeutics files SEC reports that document its clinical-stage biopharmaceutical business and its iPSC-derived cellular immunotherapy pipeline for cancer and autoimmune diseases. Current reports furnish operating results and business updates, including disclosures on FT819, FT836 and other off-the-shelf CAR T-cell programs, FDA-related development matters, clinical presentations, and costs associated with restructuring actions.
Proxy and current-report filings cover board and compensation governance, equity-plan matters, Regulation FD disclosures, and capital-structure details for FATE common stock listed on the Nasdaq Global Market. The filings also record material events affecting operations and public-company reporting obligations.